OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.

Ph III RCT SHR0302 JAK1 selective inhibitor in RA 500+ pts ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40% ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7% Safety similar other JAKi Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8

• https://twitter.com/AurelieRheumo/status/1800937920863351159/photo/1

OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6

• https://twitter.com/KDAO2011/status/1800913576238145785/photo/1

Substudy of SELECT-COMPARE trial Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX ✔️ HUmorale response 71% ✔️ Cellular response 65% ✔️ No serious AEs ✔️ One event of HZ occurred during follow up Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx

• https://twitter.com/AurelieRheumo/status/1800934293604098449/photo/1

I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e

EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’ A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr

• https://twitter.com/IMIDforum/status/1800883585177747651/photo/1
• https://twitter.com/IMIDforum/status/1800883585177747651/photo/1

More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ) Somewhat reassuring post-ORAL Surveillance infection data #EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2

• https://twitter.com/drdavidliew/status/1800922236372791605/photo/1

Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg

• https://twitter.com/drdavidliew/status/1800906791502647424/photo/1
• https://twitter.com/drdavidliew/status/1800906791502647424/photo/1

@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate @drdavidliew (NOT in support of regulation) - is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts - is the warning justified? - are there unintended consequences? @RheumNow https://t.co/TXUf90fqwN

• https://twitter.com/Yuz6Yusof/status/1800875811693867070/photo/1
• https://twitter.com/Yuz6Yusof/status/1800875811693867070/photo/1